Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo

MassMutual purchases majority interest in Counterpointe Sustainable Advisors

Retrieved on: 
Thursday, May 25, 2023
Commercial Building & Real Estate, Construction & Property, Insurance, Sustainability, Environment, Finance, Professional Services, REIT, P.C, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Bear Stearns, MassMutual, Carbon, Acquisition, Commercial property, CSRE, CIO, Entrepreneurship, Commercial, Investcorp, Counterpoint (publisher)

Massachusetts Mutual Life Insurance Company (MassMutual) today announced that it has purchased a majority interest in Counterpointe Sustainable Advisors LLC (together with its subsidiaries, collectively, “Counterpointe”), a leader in Commercial Property Assessed Clean Energy (C-PACE), sustainable real estate, and creative energy solutions financing.

Key Points: 
  • Massachusetts Mutual Life Insurance Company (MassMutual) today announced that it has purchased a majority interest in Counterpointe Sustainable Advisors LLC (together with its subsidiaries, collectively, “Counterpointe”), a leader in Commercial Property Assessed Clean Energy (C-PACE), sustainable real estate, and creative energy solutions financing.
  • “We believe Counterpointe’s extensive experience, track record, and established platform make it one of the premier leaders in the sustainable financing space for U.S. commercial real estate,” said Eric Partlan, MassMutual Chief Investment Officer.
  • “The investment from MassMutual will allow Counterpointe to expand its market leading origination platforms and establish an active impact investment management firm for debt assets including green mortgages, sustainable private debt, C-PACE and green energy finance,” said Eric J. Alini, CEO and CIO of Counterpointe.
  • and Counterpointe was represented by CS Capital Advisors LLC and Adler & Stachenfeld LLP.

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

Retrieved on: 
Monday, May 15, 2023
LLP, P.C, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Commercialization, CSL Behring, CSL, AAV, Sale, Ropes & Gray, Patient, Haemophilia, Growth, LP, ALS, Pharmaceutical industry, Real estate

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX®(etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.

Key Points: 
  • “The partial monetization of this royalty stream validates the significant potential of HEMGENIX® global sales while substantially reducing commercialization risk for uniQure.
  • The transaction is expected to close no later than 15 business days from signing.
  • HEMGENIX® is approved for the treatment of hemophilia B in the U.S., Europe and United Kingdom.
  • Sagard was represented in the transaction by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

TPG and AmerisourceBergen to Acquire Leading Specialty Practice Network OneOncology From General Atlantic

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Pharmaceutical, Managed Care, Finance, Oncology, Health, Professional Services, Other Health, Martha Plimpton, Exercise, Centerview Partners, Kidney disease, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Partnership, AmerisourceBergen, Chronic kidney disease, TPG Inc., Clinical trial, Morgan, Lewis & Bockius, Tax, P.C, Kelsey-Seybold Clinic, Research, Sidley Austin, EBITDA, Acquisition, Home, Patient, Physician, Practice management, ABC, Depreciation, Growth, EPS, General Atlantic, Paul, Weiss, Rifkind, Wharton & Garrison, Guggenheim Partners, NYSE, Data Analytics Library, Nursing, Management, Bookkeeping, TPG

TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced that they have agreed to acquire OneOncology, a network of leading oncology practices, from General Atlantic, a leading global growth equity firm.

Key Points: 
  • TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced that they have agreed to acquire OneOncology, a network of leading oncology practices, from General Atlantic, a leading global growth equity firm.
  • TPG has agreed to acquire a majority interest in OneOncology, and AmerisourceBergen will acquire a minority interest in the company.
  • TPG, AmerisourceBergen, and OneOncology’s affiliated practices, physicians, and management team will form a new joint venture that will acquire OneOncology from its existing shareholders, including current majority owner General Atlantic.
  • Centerview Partners is serving as exclusive financial advisor to OneOncology and General Atlantic, and Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as OneOncology and General Atlantic’s legal advisor.

Dallas' Caldwell Cassady & Curry Helps Nanoco Secure $150 Million Settlement with Samsung Electronics in Eastern District of Texas

Retrieved on: 
Friday, April 14, 2023
Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, IPR, Marshall, University, Samsung Electronics, QLED, PTAB, Samsung, Lawyer, Computer, Quantum, Hon, District court, Patent, Apple Inc. v. Samsung Electronics Co., Douglas v. U.S. District Court ex rel Talk America, Nanoco

The attorneys from Caldwell Cassady & Curry who successfully represented Nanoco include lead trial counsel and firm principal Brad Caldwell , fellow firm principals Austin Curry , Warren McCarty , Hamad Hamad , Brian Johnston , Chris Stewart , Seth Reich , and associates Alex Waldrop , Bjorn Blomquist , and Xu Zhou .

Key Points: 
  • The attorneys from Caldwell Cassady & Curry who successfully represented Nanoco include lead trial counsel and firm principal Brad Caldwell , fellow firm principals Austin Curry , Warren McCarty , Hamad Hamad , Brian Johnston , Chris Stewart , Seth Reich , and associates Alex Waldrop , Bjorn Blomquist , and Xu Zhou .
  • Nanoco also was represented by lawyers from Boston-based Mintz, Levin, Cohn, Ferris, Glovsky and Pompeo, and Longview, Texas-based Ward, Smith & Hill.
  • The lawsuit was filed in 2020 based on infringement of a series of Nanoco patents covering its quantum dot technology.
  • In its ruling, the PTAB found in favor of Nanoco related to all 47 claims covering five of the company's patents contested by Samsung.

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

Retrieved on: 
Wednesday, April 5, 2023
Biotechnology, University, DNA, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, PC, Virginia School for Girls, Therapy, Patient, Harvard University, Management

has been appointed chief legal officer and secretary.

Key Points: 
  • has been appointed chief legal officer and secretary.
  • “We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio.
  • “Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA therapeutics that have the potential to transform the lives of patients with rare and prevalent diseases across the globe,” said Yalonda Howze, J.D., chief legal officer and secretary of Generation Bio.
  • She most recently served as chief legal officer, chief compliance officer and corporate secretary of Codiak BioSciences.

SILAC Insurance Company and Hildene Capital Management Announce Strategic Alliance

Retrieved on: 
Monday, January 9, 2023
Professional Services, Data Analytics, Insurance, Finance, Asset Management, Consulting, Kramer Levin Naftalis & Frankel, Multimedia, Goldman Sachs, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, SILAC, Financial adviser, Financial services, Hildene

SILAC Insurance Company (“SILAC” or the “Company”), a leading U.S. annuity provider, and Hildene Capital Management, LLC (together with its affiliates and clients, “Hildene”), a credit-focused asset manager with approximately $12 billion of assets under management, today announced that they have entered into a long-term strategic alliance.

Key Points: 
  • SILAC Insurance Company (“SILAC” or the “Company”), a leading U.S. annuity provider, and Hildene Capital Management, LLC (together with its affiliates and clients, “Hildene”), a credit-focused asset manager with approximately $12 billion of assets under management, today announced that they have entered into a long-term strategic alliance.
  • View the full release here: https://www.businesswire.com/news/home/20230109005283/en/
    As part of the alliance, Hildene has acquired a strategic minority ownership interest in the Company.
  • Stephen C. Hilbert, Chairman and Chief Executive Officer of SILAC, said, “I couldn’t be more pleased to form this strategic alliance with Hildene, a well-recognized credit investor with a disciplined approach to portfolio management.
  • Our alliance with SILAC underscores the confidence we have in the Company’s ongoing success and Hildene’s ability to source attractive investment opportunities for longer-term capital.

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

Retrieved on: 
Monday, January 9, 2023
Banking, Research, General Health, Professional Services, Pharmaceutical, Oncology, Clinical Trials, Science, Biotechnology, FDA, Finance, Health, Other Science, BOLD, Itch, Ageing, Primary sclerosing cholangitis, Institute of Liver and Biliary Sciences, Cirrhosis, Food, PSC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hope, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Science, Liver failure, Acquisition, Partner, Patient, IPN, Alagille syndrome, Liver disease, Hart–Scott–Rodino Antitrust Improvements Act, Albireo, Liver transplantation, Biliary atresia, Bile, CVR, Paul, Weiss, Rifkind, Wharton & Garrison, FDA, Webcast, Genetic disorder, ADR, Goldman Sachs, IND, Apache iBATIS, Rare disease, Centerview Partners, P.C, Phase, NTCP, Liver, Medical imaging, Pharmaceutical industry, Ipsen, PFIC, Euronext

Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

Key Points: 
  • Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
  • “Our Rare Disease franchise is strengthened with Bylvay, which, in addition to being the first-approved treatment in PFIC, has two further indications being investigated in rare liver conditions that are underserved.
  • “Our talented team at Albireo have advanced the first Phase III studies in three different pediatric liver diseases while discovering two promising new clinical stage bile acid modulators.
  • Goldman Sachs is acting as exclusive financial advisor to Ipsen and Orrick Herrington & Sutcliffe LLP as legal counsel to Ipsen.

CROWN HOLDINGS APPOINTS TWO NEW INDEPENDENT DIRECTORS TO BOARD

Retrieved on: 
Tuesday, December 13, 2022
Security (finance), P.C, Boston University School of Law, Annual general meeting, Gordon, CCK, AGM, FirstEnergy, United Kingdom company law, University, Southwest Gas, Icahn Enterprises, Bachelor of Arts (film), Eric Gleacher, Food packaging, General counsel, 8-K, The Manitowoc Company, Wendell Pritchett, Natural gas, Annual report, Electric Bond and Share Company v. Securities and Exchange Commission, NYSE, Assistant, Dechert, Crown Holdings, Fir Tree, Senior, Equity, Nomination, Wharton School of the University of Pennsylvania, Marketing, Corporate Affairs, Machine learning, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Management, Crown, Xerox, Icahn

YARDLEY, Pa., Dec. 13, 2022 /PRNewswire/ -- Crown Holdings, Inc. (NYSE: CCK) ("Crown" or the "Company") today announced that it has entered into an agreement with Icahn Enterprises L.P., whereby Jesse Lynn and Andrew Teno, General Counsel of Icahn Enterprises and Portfolio Manager of Icahn Capital, respectively, will join the Company's Board of Directors, effective immediately. Mr. Lynn and Mr. Teno will also stand for election at the Company's upcoming 2023 Annual Meeting of Shareholders ("2023 AGM"), and Crown has agreed to include Mr. Teno and Mr. Lynn on its recommended slate of nominees for election at the Company's 2023 AGM.

Key Points: 
  • With the additions of Mr. Lynn and Mr. Teno, the Crown Board will expand to 13 directors, 12 of whom are independent.
  • Since 2019, the Company has refreshed over half the Board and added eight new independent directors, including the appointments announced today.
  • We welcome Jesse and Andrew to the Board and look forward to working together to deliver enhanced value for Crown shareholders."
  • During his time at Fir Tree, he also served on the Board of Directors of Eco-Stim Energy Solutions.

Steven P. Rosenthal Gives a Second $1 Million to Support Innovation at Northeast Arc

Retrieved on: 
Tuesday, November 22, 2022
General Health, Fund Raising, Health, Foundation, Philanthropy, Trustee, Habilitation, Family support, Robert Rosenthal (businessman), Massachusetts Convention Center Authority, Multimedia, Liberty Tree Mall, Swedish National Board of Institutional Care, Ruderman Family Foundation, Black box theater, Acquisition, Disability, Rosenthal, Gold, State Employment Service (Azerbaijan), AIPAC, Transition, Loomis, City, Harvard College, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Heart, Risk, Boston University, Richard P. Rosenthal, Pharmaceutical industry, Management, Recreation

Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.

Key Points: 
  • Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.
  • Pictured from left: J.J.s father John Millard, J.J., his mother Joanna Millard, Rosenthal and Jo Ann Simons, President & CEO Northeast Arc.
  • He hopes the new gift will continue to encourage others to support Northeast Arc as well.
  • When Steve made his initial $1 million donation it was a real game-changer for us, said Jo Ann Simons , President and CEO of Northeast Arc.

Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners

Retrieved on: 
Monday, October 31, 2022
Health, Pharmaceutical, Morgan Stanley, U.S. Securities and Exchange Commission, Brain, Private Securities Litigation Reform Act, Culture, Forward-looking statement, Patient, IV, Tuberous sclerosis, Adult, CDKL5, Clinical trial, Marinus, Company, EMA, Security (finance), Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Medication, FDA, Epilepsy, Ganaxolone, CV, Seizure, GABAA, Ecosystem, Achievement, COVID-19, Therapy, Pharmaceutical industry, Sagard

The total amount payable by Marinus to Sagard is capped at 1.9x of the upfront payment, with the ability to redeem the revenue interest financing agreement at lower multiples within the first four years from funding.

Key Points: 
  • The total amount payable by Marinus to Sagard is capped at 1.9x of the upfront payment, with the ability to redeem the revenue interest financing agreement at lower multiples within the first four years from funding.
  • Upon achievement of the cap amount, the revenue interest financing agreement will terminate.
  • Sagard is excited to complete this transaction with Marinus and help support the ongoing launch of ZTALMY and the development of ganaxolone, said Raja Manchanda, Partner at Sagard.
  • As a firm, Sagard operates platforms that invest across five asset classes: venture capital, private equity, private credit, real estate and healthcare royalties.